"Olaparib Significantly Prolongs PFS In Metastatic BRACA-Related Breast Cancer" - ME Robson
Olaparib significantly prolonged PFS compared with chemotherapy among patients with HER-2-negative metastatic breast cancer, according to a study. “In this trial, the response rate to the PARP inhibitor was double that of standard chemotherapy, the chance of progression decreased by 42 percent at a median follow up of 14 months,” said Amy Tiersten, MD, professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai. “Because olaparib is a targeted agent, there were fewer side effects and better quality of life among the women randomly assigned to receive the PARP inhibitor when compared with standard chemotherapy.”
- Amy Tiersten, MD, Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai